Background. There is still considerable uncertainty as to the best algorithm for interpreting human immunodeficiency virus (HIV) genotyping results.
of antiretroviral therapy in HIV-infected patients with treatment failure, compared with the empirical selection of drugs for a salvage regimen [3] [4] [5] [6] [7] .
Identifying an effective algorithm for interpreting the results is crucially important for the management of HIV-infected patients who experience failure of their current antiretroviral regimen. Two such algorithms are RetroGram (Virology Education) and VirtualPhenotype (Virco). The former is a rule-based interpretation (RBI) algorithm that takes into account updated published data concerning resistance and virological response to each considered drug in the presence of defined sets of mutations; the latter is a virtual phenotype interpretation (VPI) method that predicts the HIV phenotype on the basis of the correlation between phenotype and genotype in the presence of a given set of mutations, as inferred from a database of paired genotypes and phenotypes [8] .
One retrospective analysis suggested that rule-based algorithms may be more predictive of response than an early version of virutal phenotyping [9] , but only 1 study has made a randomized comparison of rule-based and phenotype predictionbased algorithms [10] . It has been shown that expert advice further improves the performance of genotype resistance testing [7] , but, because such advice is often unavailable in many clinical settings, it is important to identify an interpretative algorithm with results that are easily understood by most clinicians caring for HIV-infected patients.
The aim of the Mutations and Salvage (MuSa) study was to compare the efficacy of a rule-based algorithm with that of a phenotype-based algorithm for interpreting HIV genotyping as a means of guiding salvage regimens under conditions that reflect the real-world scenario of HIV treatment, in which expert advice is largely unavailable.
METHODS

Study design. From 2001 through 2003
, subjects experiencing failure of their first or second HAART regimen were recruited and enrolled in 41 centers throughout Italy. The study protocol was approved by each local ethics committee, and all of the participants gave their informed consent.
After being stratified into 3 groups on the basis of their treatment history (group 1, nonnucleoside reverse-transcriptase inhibitor (NNRTI)-naive, protease inhibitor (PI)-experienced patients; group 2, PI-naive, NNRTI-experienced patients; and group 3, PI-and NNRTI-experienced patients), the patients were centrally randomized (1:1) at the coordinating site (San Raffaele Hospital, Milan, Italy) to receive treatments modified on the basis of the results of HIV genotyping, as interpreted by the VirtualPhenotype system, version 3.0.00-3.3.00 (Virco), with the first-generation biological cut-off points [8] available during the course of the study (VPI arm) or by the RetroGram rule-based system, version 1.4-1.6i (RetroGram) (RBI arm). All of the enrolled subjects were nucleoside reverse-transcriptase inhibitor (NRTI) experienced and, on the basis of VPI or RBI results, were prescribed a new antiretroviral regimen of at least 3 drugs (including at least 1 NRTI and 1 PI). The NNRTInaive patients were also prescribed an NNRTI. Only drugs licensed in Italy were allowed to be administered. In particular, enfuvirtide was not prescribed to any of the patients enrolled in the study, lopinavir-ritonavir was available from the begin- ning of the study, and tenofovir was available during the last year of the study.
Virological methods. All of the patients had virus genotyped by the Virology Laboratory of San Raffaele Hospital. HIV RNA was extracted using a QIAmp Viral RNA kit (Qiagen) and retrotranscribed to cDNA using Expand Reverse Transcriptase (Roche Diagnostics). The cDNA was amplified by means of 2 nested reactions using the Expand High Fidelity PCR System Kit (Roche Diagnostics) and oligonucleotide primers (Virco). The amplification primers were purified using the QIAquick kit (Qiagen). Megabace 1000 (Amersham Biosciences) was used for sequencing, and the sequences were assembled by a Sequencer (Genecodes).
HIV RNA level was assessed in each center by means of branched DNA (Versant RNA, version 3.0 [Bayer] ), Amplicor (Monitor test, version 1.5 [Roche Diagnostics]) or nucleic acid sequence-based amplification (Nuclisens, version 2.1 [BioMerieux] ). All of the tests had a quantification limit of !400 copies/mL. VPI and RBI genotype interpretation and definition of drug activity. In the VPI assay [8] , the patient's set of mutated amino acids is processed against a constantly growing genotypephenotype-correlated dataset (at the time of the study, the dataset contained 128,000 sets of clinically isolated HIV-1 genotypes and matching drug-susceptibility phenotypes) and used to predict drug susceptibilities by retrieving phenotypic results for isolates with the same mutational profile from the genotype-phenotype correlated database. Two possibilities can be distinguished at this point: if the database returns у10 matches, a mean fold-resistance is calculated for each drug; if it returns !10 matches, VPI falls back on a rules-based interpretation of the mutation profile of the new isolate in combination with all of the available quantitative data and offers a qualitative prediction of "likely" or "unlikely" drug resistance.
RetroGram addresses the use of each antiretroviral drug by ranking them according to published data concerning their anticipated activity against pathogens with a given set of mutations. Each drug is classified into 1 of 5 ranks: A, the drug should be preferentially used; B, the drug should be used only if no rank A drug is available or can be administered; C, the drug should be used only if no drug in rank A or B is available or can be administered; D, the drug should be used only if no Figure 2 . Reverse-transcriptase (RT) drug-resistance mutations at baseline in the rule-based interpretation (RBI) arm and the virtual phenotype interpretation (VPI) arm of the study. Asterisk indicate mutations for which a statistically significant difference between arms was detected ( ). P ! .05 drug in rank A, B, or C is available or can be administered; and U (i.e., unranked), no indication concerning the drug can be provided on the basis of the available data.
To compare data for antiretrovirals in the VPI and RBI arms, the VPI outputs of "resistance" (i.e., a higher estimated foldresistance than the biological cut-off point) and "resistance likely" were pooled, and the proportion of patients with virus resistant to each drug was compared with the proportion of patients with virus for which RBI placed the same drug in rank C or D.
Each patient was similarly assigned a regimen activity score (i.e., the number of drugs initially received that could be considered "active" on the basis of the HIV genotype interpretation provided by the algorithm to which the patient was randomized); this score was 3 if all 3 drugs of the new treatment regimen were classified as "sensitive" or "resistance unlikely" by VPI or ranked A or B by RBI. The patients starting a new regimen with only 1 or 2 drugs classified as "sensitive" or "resistance unlikely" by VPI or ranked A or B by RBI were assigned a regimen activity score of 1 or 2.
Statistical analyses. The primary end point was a decrease in HIV RNA level to !400 copies/mL at week 12, as assessed by on-treatment (OT) analysis (including only those patients who were still receiving the regimen prescribed on the basis of the results of their baseline resistance testing). The secondary end points were the quantitative decrease in HIV RNA level and the increase in CD4 + T lymphocyte count at week 4, 12, and 48 and the probability of maintaining an HIV RNA level of !400 copies/mL at week 48, also assessed by OT analysis.
A sample size of 480 patients was required for the estimated probability of reaching the primary end point to be 60% in arm A and 45% in arm B; the expected dropout rate was 25%, Figure 3 . Protease drug-resistance mutations at baseline in the rule-based interpretation (RBI) arm and the virtual phenotype interpretation (VPI) arm of the study.
and power was fixed at 80% ( , with ). The b p 80% a p 5% OT analyses excluded the patients whose treatment was modified for any reason, thus considering only patients still receiving treatment with the same regimen that had been prescribed according to the results of resistance testing at baseline. The intention-to-treat (ITT) analyses were made on the basis that missing data or noncompletion of treatment equaled treatment failure.
Categorical variables were compared between arms using distribution frequencies, with the x 2 or Fisher's exact test being used to identify any statistically significant differences; the latter was used when the former was inappropriate, because the expected frequency of observations in at least 1 cell was !5. Continuous variables were compared between arms by calculating their mean and median values, SDs, and interquartile ranges, with Student's t test being used to determine whether the differences were statistically significant. Statistical significance was defined as a 2-tailed P value of !.05. Because of the skewed nature of the plasma HIV RNA dataset, a logarithmic transformation was considered.
Multiple-logistic regression analyses were used to estimate the adjusted between-arm OR (arm A vs. arm B) of having HIV RNA levels of !400 copies/mL 12 weeks after randomization. The variables included in the multivariable analysis (those considered to be the most clinically relevant in the studied circumstances) were baseline HIV RNA level, CD4 + T lymphocyte count, Centers for Disease Control and Prevention disease stage (A or B vs. C), drug experience (3-class vs. 2-class experienced), number of reverse-transcriptase (RT) mutations, and number of protease mutations. All analyses were performed by SAS software, version 8.2 (SAS).
RESULTS
Enrollment began in June 2001 and was terminated 2.5 years after the first patient was enrolled, because no further patients could be recruited by any center, probably because of the widespread availability of new drugs through expanded access programs and the wider availability of resistance testing. The data refer to the 318 patients who were randomized up to 20 December 2003. Figure 1 shows patient disposition throughout the 48 weeks of the study, and table 1 summarizes the patients' characteristics at baseline; the only statistically significant between-arm difference at baseline was with respect to the mean number of RT mutations per subject, which was higher in the VPI arm (5.2 vs. 4.3; ). P p .005 There was no statistically significant difference between the 2 arms in terms of ongoing antiretroviral treatment at enrollment. Figures 2 and 3 show the prevalence of RT and protease drug-resistance mutations at baseline. The only statistically significant differences between the VPI and RBI arms were with respect to the proportion of patients with the RT 41L (45.9% vs. 35.1%;
) and RT 184V mutation (76.4% vs. 67.6%; P p .03 ), which was higher in the VPI arm, and the proportion P p .04 of patients with the RT 75T/I mutation (5.4% vs. 0.6%; P p ), which was higher among those randomized to the RBI .02 arm.
The VPI and RBI systems differently assessed the use of 8 (50%) of 16 drugs (table 2). Only 4 (25%) of the 16 drugs were actually prescribed in significantly different proportions in the 2 arms; the drugs that were more frequently prescribed in the VPI arm were stavudine (51.6% vs. 35.5%; ) P p .006 and nelfinavir (19.3% vs. 5.8%; ) , and the drugs that P p .0006 were more frequently prescribed in the RBI arm were lamivudine (34.8% vs. 23.6%;
) and lopinavir-ritonavir P p .03 (46.5% vs. 31.7%;
). The mean (‫ע‬SD) regimen activity P p .01 scores in the VPI and RBI arms were and 2.8 ‫ע‬ 0.7 2.7 ‫ע‬ , respectively ( ). 0.9 P p .15 Primary end point. The OT analysis showed that 132 (68.8%) of 192 patients had plasma HIV RNA levels of !400 copies/mL at week 12, including 65 (66.3%) of 98 patients in the VPI arm and 67 (71.3%) of 94 patients in the RBI arm ( ) ( figure 4 ). The risk difference was 4.95 (95% CI, P p .46 Ϫ8.13 to 18.03).
Secondary end points.
The ITT analysis showed that the proportion of patients with plasma HIV RNA levels of !400 copies/mL at week 12 was 40.4% in the VPI arm and 42.7% in the RBI arm (
). There was no between-arm difference P p .68 in the proportion of patients with HIV RNA levels of !400 copies/mL at week 4, 24, 36, or 48 according to either OT (figure 4) or ITT analysis. In particular, by ITT analysis, the proportion of patients with plasma HIV RNA levels of !400 copies/mL at week 48 was 23.6% in the VPI arm and 29.9% in the RBI arm ( ). The risk difference at this time point P p .2 by ITT analysis was 6.33 (95% CI, Ϫ3.38 to 16.05). KaplanMeier analysis showed that there was also no between-arm difference in the cumulative probability of maintaining a virological response at week 48 ( , by log-rank test). There P p .45 were also no between-arm differences in the mean HIV RNA concentrations or in CD4 + T lymphocyte counts at any time point during the 48 weeks of observation, by either OT ( figure  5 ) or ITT analysis. At week 12, the proportion of 2-class-experienced patients with HIV RNA levels of !400 copes/mL was significantly greater than that of  ). However, the randomization arm did P p .01 not influence this result, because OT analysis showed that the end point was reached by 75.4% of the 2-class-experienced subjects in the VPI arm and 75.9% of those in the RBI arm ( ), and the corresponding proportions of 3-class-ex-P p .95 perienced subjects in the 2 arms were 51.4% and 65%, respectively ( ). P p .22 Multivariable analysis. The results of the multiple-logistic regression analysis are given in table 3. The OT analysis showed that the only independent correlates of virological response at week 12 were HIV RNA level at baseline (OR per log 10 copies/ mL, 0.55; 95% CI, 0.32-0.95;
) and CD4 + T lympho-P p .032 cyte count at baseline (OR per 50-cell increment, 1.08; 95% CI, 1-1.16; ). The ITT analysis confirmed only baseline P p .048 CD4 + T lymphocyte count (OR per 50-cell increment, 1.07; 95% CI, 1.02-1.12;
) as independently predicting the P p .008 12-week virological response. On-treatment analysis of virological response (defined as an HIV RNA level of !400 copies/mL) through 48 weeks of follow-up for patients randomized to either the virtual phenotype interpretation (VPI) arm or the rule-based interpretation (RBI) arm. The primary end point was at 12 weeks. BL, baseline.
DISCUSSION
Despite the proven usefulness of HIV drug-resistance testing, there is still considerable uncertainty as to the best algorithm for interpreting genotyping results [11] . Various algorithms have been proposed, but their clinical efficacy has been tested in only 1 other randomized clinical trial, in which Torti et al. [10] found no statistically significant between-arm difference in the efficacy of salvage regimens of antiretroviral drugs selected (with the help of an expert) on the basis of the HIV genotype interpretation offered by an RBI algorithm (Visible Genetics) or VPI algorithm.
Our results show that both algorithms were effective in guiding salvage therapies. No statistically significant differences between them were observed for our study population, although the smaller number of RT mutations at baseline in the RBI arm may have slightly favored the outcomes of the patients randomized to receive a new regimen on the basis of the results of this test. However, it seems unlikely that this small, betweenarm difference at baseline had any meaningful effect on the overall results. Because the biological cutoff points of the VPI algorithm used in the course of this study are no longer applied and because some of the rules of the RBI algorithm used in the course of this study have changed, we cannot exclude the possibility that our results might have been different if we had used the updated or future versions of the 2 algorithms.
The algorithms proved to be comparably efficacious, despite significant differences in the way in which each algorithm addressed the use of individual drugs and the consequent significant difference in their actual use in the 2 arms. A possible reason for this is that errors in the use of 1 or more drugs in 1 arm were compensated for by errors made in the other arm. However, a significant between-arm difference in actual drug prescription was found for only one-quarter of the patients. It is probable that differences in genotype interpretation do not always lead to differences in drug prescription, because the latter involves the global clinical evaluation of a patient and not just the evaluation of the patient's viral genotype.
We used 12-week virological outcome as our primary end point to allow comparison with other studies [1, [4] [5] [6] and because long-term changes in antiretroviral regimens are frequent and usually caused by toxicity and decreasing levels of compliance, rather than by virological failure [12] . However, our short-term result was confirmed by our extended, 48-week observations. Previous studies have shown that expert advice significantly increases the chance of identifying an effective salvage regimen [7] , but we decided to test the efficacy of the 2 tests in a "real world" setting, in which expert advice is not easily available. Our findings indicate that, if the results of drugresistance testing (i.e., the interpretation provided by an algorithm) are presented in a clear fashion, even clinicians who are not expert in the field of HIV drug resistance can select effective drugs for a salvage regimen. However, we cannot exclude the possibility that the accompaniment of expert advice would lead to even better results.
The study was initially planned to enroll 480 patients and to have 80% power in detecting a 15% difference between the arms in terms of the primary end point. The enrollment target was not reached (meaning that the power ratings of the OT and ITT analyses were 50% and 70%, respectively) but, given the small difference found in virologic outcome between arms, even if the target sample size had been reached, it is unlikely that we would have found a difference 115%. Nevertheless, we cannot exclude the possibility that minor (but potentially clinically relevant) differences exist.
We concentrated on the OT analysis, because we believe that this is the best means of evaluating the efficacy of any diagnostic tool. We believe that the performance of drug-resistance testing is best assessed in patients receiving all of the drugs selected on the basis of the results of the test (the best possible regimen in the given setting) and that any therapeutic failures due to treatment withdrawal or missed visits should not be attributed to the test itself. However, we also made an ITT analysis, and the results did not lead us to change our conclusions. Our findings are consistent with those of the Resistance and Dosage Adapted Regimens Study, in which the genotype interpretations obtained using the VPI or RBI algorithms did not lead to any major differences in the virological outcome, probably as a consequence of the availability of expert advice [10] . However, because our study was free of this possible bias, our findings can be generalized to the many clinical settings in which the interpretation of HIV genotyping by experts is not a usual component of care or part of the normal clinical decision-making process when a patient no longer responds to a given antiretroviral therapy. The consistency between our results and those of the Resistance and Dosage Adapted Regimens (RADAR) Study also suggests that the efficacy of VPI and RBI algorithms is comparable.
Finally, although the long-term efficacy of drug-resistance testing for managing the cases of patients who are experiencing failure of antiretroviral drugs has been questioned [13] , the sustained reduction in viral load and the duration of immune recovery observed throughout the 48 weeks of our study suggest that this diagnostic procedure provides more than a short-term benefit. In conclusion, the versions of both the RBI and VPI algorithms used during the course of our study were able to guide the selection of effective antiretroviral drugs for a salvage regimen, with no large differences between treatment arms with regard to outcome.
